<?xml version="1.0" encoding="UTF-8"?>
<p>The urgently launched clinical trials worldwide on investigational medicinal products for the current COVID-19 outbreak should read out within weeks to months. We can anticipate the notion of drug repurposing for emerging viral diseases to be scrutinized based on these results. At a deeper level, this is a battle not only against COVID-19 but for the very soul concept of new antimicrobials and their clinical indications: ‘one drug, one virus versus one drug, multiple viruses or multiple drugs, one virus are the contenders’ [
 <xref rid="B19" ref-type="bibr">19</xref>,
 <xref rid="B20" ref-type="bibr">20</xref>].
</p>
